Personalis (NASDAQ:PSNL) Now Covered by Analysts at Lake Street Capital

Lake Street Capital began coverage on shares of Personalis (NASDAQ:PSNL) in a research report sent to investors on Tuesday, Benzinga reports. The brokerage issued a buy rating and a $4.00 price target on the stock.

Separately, Needham & Company LLC reissued a buy rating and set a $3.50 price target on shares of Personalis in a research report on Thursday, April 11th.

Personalis Stock Down 3.8 %

Shares of PSNL stock opened at $1.54 on Tuesday. Personalis has a 52 week low of $0.89 and a 52 week high of $2.60. The firm’s 50-day simple moving average is $1.46 and its two-hundred day simple moving average is $1.43.

Personalis (NASDAQ:PSNL) last posted its quarterly earnings data on Wednesday, February 28th. The company reported ($0.46) earnings per share for the quarter, beating the consensus estimate of ($0.53) by $0.07. The firm had revenue of $19.68 million for the quarter, compared to analysts’ expectations of $19.56 million. Personalis had a negative net margin of 147.38% and a negative return on equity of 61.42%. Research analysts expect that Personalis will post -1.58 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Prime Capital Investment Advisors LLC purchased a new position in Personalis during the 3rd quarter valued at about $36,000. Pathstone Family Office LLC raised its holdings in Personalis by 149.3% in the third quarter. Pathstone Family Office LLC now owns 37,081 shares of the company’s stock worth $45,000 after buying an additional 22,204 shares during the last quarter. Quadrature Capital Ltd bought a new position in shares of Personalis in the fourth quarter worth approximately $152,000. Bruce & Co. Inc. grew its holdings in shares of Personalis by 100.0% during the fourth quarter. Bruce & Co. Inc. now owns 300,000 shares of the company’s stock valued at $630,000 after buying an additional 150,000 shares during the last quarter. Finally, GSA Capital Partners LLP raised its holdings in Personalis by 6.2% in the 1st quarter. GSA Capital Partners LLP now owns 420,141 shares of the company’s stock worth $626,000 after acquiring an additional 24,498 shares during the last quarter. Institutional investors own 61.91% of the company’s stock.

Personalis Company Profile

Personalis, Inc develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.